NCT06413212Recruiting
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
Source: ClinicalTrials.gov · Last updated 4 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 55 (estimated)
- First submitted
- 14 Jan 2024
- Start date
- 4 Aug 2023
- Primary completion date
- Dec 2025
- Lead sponsor
- Liu Huang
- NCT number
- NCT06413212
What you commit to
- Study type: Observational
- Planned participants: 55
- From 4 Aug 2023 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with cognitive disorder, mental diseases and terrible compliance.
- Allergic to known chemotherapeutic agents.
Other
- Pregnant or lactating women.
- Have Participated other clinical trials in six months.
- Severe liver dysfunction.
- Severe renal dysfunction.
- Other circumstance not suitable to participate in this trial determined by investigators.
Who the study is looking for
- 18 to 75 years old, regardless of gender.
- Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023.
- Advanced and unresectable malignancy confirmed by biopsy diagnosis.
- Able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases.
- Score of eastern cooperative oncology group (ECOG) is not higher than 2, ECOG≤2.
- Anticipated survival exceed six months.
- At least one measurable lesions (according to RECIST 1.1)
- Resistance or intolerance to standard therapy regimens.
- Signed informed consent form voluntarily.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.